标题
Trastuzumab in the Treatment of Breast Cancer
作者
关键词
Breast Cancer, Trastuzumab, Human Epidermal Growth Factor Receptor, Advanced Breast Cancer, Lapatinib
出版物
BIODRUGS
Volume 30, Issue 2, Pages 75-86
出版商
Springer Nature
发表日期
2016-02-19
DOI
10.1007/s40259-016-0162-9
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) E. Senkus et al. ANNALS OF ONCOLOGY
- Therapeutic approach to the management of HER2-positive breast cancer metastatic to the brain
- (2015) Ajay Patil et al. CANCER LETTERS
- Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice
- (2015) S. Antolín-Novoa et al. Clinical & Translational Oncology
- Subcutaneous Trastuzumab for HER2-positive Breast Cancer – Evidence and Practical Experience in 7 German Centers
- (2015) C. Jackisch et al. GEBURTSHILFE UND FRAUENHEILKUNDE
- Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials
- (2015) Ciara C. O'Sullivan et al. JOURNAL OF CLINICAL ONCOLOGY
- ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†
- (2014) F. Cardoso et al. ANNALS OF ONCOLOGY
- Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study
- (2014) X. Pivot et al. ANNALS OF ONCOLOGY
- HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development
- (2014) J C Singh et al. BRITISH JOURNAL OF CANCER
- Features of breast cancer in developing countries, examples from North-Africa
- (2014) Marilys Corbex et al. EUROPEAN JOURNAL OF CANCER
- Subcutaneous Administration of Monoclonal Antibodies in Oncology
- (2014) C. Jackisch et al. GEBURTSHILFE UND FRAUENHEILKUNDE
- Risk of Trastuzumab-Related Cardiotoxicity in Early Breast Cancer Patients: A Prospective Observational Study
- (2014) Jian Xue et al. Journal of Breast Cancer
- Safety and Tolerability of Docetaxel, Cyclophosphamide, and Trastuzumab Compared to Standard Trastuzumab-Based Chemotherapy Regimens for Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
- (2014) Potjana Jitawatanarat et al. Journal of Breast Cancer
- Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
- (2014) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer
- (2014) John M. Lambert et al. JOURNAL OF MEDICINAL CHEMISTRY
- Is it safe to give anthracyclines concurrently with trastuzumab in neo-adjuvant or metastatic settings for HER2-positive breast cancer? A meta-analysis of randomized controlled trials
- (2014) Feng Du et al. MEDICAL ONCOLOGY
- Herceptin Resistance Database for Understanding Mechanism of Resistance in Breast Cancer Patients
- (2014) Sahil Ahmad et al. Scientific Reports
- Monoclonal antibodies: Pharmacokinetics as a basis for new dosage regimens?
- (2014) J-R Azanza et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab
- (2013) W. J. Gradishar ANNALS OF ONCOLOGY
- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2013) E. Senkus et al. ANNALS OF ONCOLOGY
- Trastuzumab for patients with HER2 positive breast cancer: Delivery, duration and combination therapies
- (2013) Ana Catarina Pinto et al. BREAST
- Biological therapies in breast cancer: Common toxicities and management strategies
- (2013) Romualdo Barroso-Sousa et al. BREAST
- Co-targeting estrogen receptor and HER2 pathways in breast cancer
- (2013) Arjun Mehta et al. BREAST
- Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis
- (2013) Flora Zagouri et al. BREAST CANCER RESEARCH AND TREATMENT
- Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy males
- (2013) Chris J. Wynne et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Optimal Targeting of HER2–PI3K Signaling in Breast Cancer: Mechanistic Insights and Clinical Implications
- (2013) Brent N. Rexer et al. CANCER RESEARCH
- Molecular determinants of trastuzumab efficacy: What is their clinical relevance?
- (2013) Pradip De et al. CANCER TREATMENT REVIEWS
- Trastuzumab in small tumours and in elderly women
- (2013) Joan Albanell et al. CANCER TREATMENT REVIEWS
- SEOM Clinical Guidelines for the systemic treatment of early breast cancer 2013
- (2013) S. Del Barco et al. Clinical & Translational Oncology
- Trastuzumab Emtansine: First Global Approval
- (2013) Anita Ballantyne et al. DRUGS
- Targeted therapy for HER2 positive breast cancer
- (2013) Jason A Incorvati et al. Journal of Hematology & Oncology
- Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study
- (2013) Xavier Pivot et al. LANCET ONCOLOGY
- 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial
- (2013) Xavier Pivot et al. LANCET ONCOLOGY
- Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial
- (2013) Aman U Buzdar et al. LANCET ONCOLOGY
- Le trastuzumab dans le traitement adjuvant du cancer du sein
- (2013) Nabil Ismaili et al. PRESSE MEDICALE
- The war on cancer: are we winning?
- (2013) M. J. Duffy TUMOR BIOLOGY
- Treating Breast Cancer in the 21st Century: Emerging Biological Therapies
- (2013) Gabriel Tinoco et al. Journal of Cancer
- 1st International consensus guidelines for advanced breast cancer (ABC 1)
- (2012) F. Cardoso et al. BREAST
- Optimal Management of Brain Metastases from Breast Cancer
- (2012) Rupert Bartsch et al. CNS DRUGS
- The global breast cancer burden
- (2012) John R Benson et al. Future Oncology
- US Food and Drug Administration Approval Overview in Metastatic Breast Cancer
- (2012) Patricia Cortazar et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2-Positive Breast Cancer
- (2012) Chris Wynne et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial
- (2012) Gustavo Ismael et al. LANCET ONCOLOGY
- Intrathecal administration of trastuzumab with cytarabine and methotrexate in breast cancer patients with leptomeningeal carcinomatosis
- (2011) Michal Mego et al. BREAST
- Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab
- (2011) Mafalda Oliveira et al. BREAST CANCER RESEARCH AND TREATMENT
- Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31
- (2011) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Meta-analysis of concomitant compared to sequential adjuvant trastuzumab in breast cancer: the sooner the better
- (2011) Fausto Petrelli et al. MEDICAL ONCOLOGY
- Adjuvant Trastuzumab in HER2-Positive Breast Cancer
- (2011) Dennis Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Spotlight on Trastuzumab as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer†
- (2010) Karly P. Garnock-Jones et al. BIODRUGS
- Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer
- (2010) Anna Emde et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
- (2010) Luca Gianni et al. LANCET
- Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer
- (2009) C. Ferrario et al. ANNALS OF ONCOLOGY
- Breast cancer as a global health concern
- (2009) Steven S. Coughlin et al. Cancer Epidemiology
- Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab
- (2008) Mariantonietta Colozza et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Trastuzumab
- (2008) Kate McKeage et al. PHARMACOECONOMICS
- Herceptin and breast cancer: An overview for surgeons
- (2008) N. Patani et al. SURGICAL ONCOLOGY-OXFORD
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started